4 / 21
Page 34
December 06-07 , 2018
Amsterdam, Nether l ands
Journal of Neuropsychiatry
ISSN: 2471-8548
Alzheimer’s and Dementia 2018
1 3
t h
W o r l d c o n g r e s s o n
Alzheimer’s and Dementia
Objective:
Recent studies suggest that cholinergic dysfunction does not provide a complete account of age-related cognitive
deficits and other neuronal systems like monoaminergic hypofunction. In several studies, selective serotonin reuptake inhibitors
demonstrated promotion in neurogenesis in the hippocampus and enhanced memory and cognition. The aim of this study is to
survey the effect of serotonin augmentation on cognition and activities of daily living in patients with Alzheimer’s disease.
Method:
The trial was designed as a 12-week randomized, placebo controlled, double-blind study. 122 patients aged 55 to 85
years with mild-to-moderate Alzheimer’s dementia were randomly allocated in one of the three treatment groups: fluoxetine plus
rivastigmine, rivastigmine alone or placebo group. Efficacy measures comprised assessments of cognition, activities of daily
living and global functioning. Hamilton depression scale also was used to assess changes in mood throughout the study.
Result:
Fluoxetine plus rivastigmine and rivastigmine groups demonstrated improvement on measures of cognitive and memory
without any significant difference. However, the former group did better in their activities of daily living and global functioning.
Patients taking placebo had significant deterioration in all the efficacy measures. Patients taking rivastigmine or rivastigmine
plus fluoxetine had improvements in Hamilton depression scale without significant differences.
Conclusions:
Concomitant use of selective serotonin-enhancing agents and acetyl cholinesterase inhibitors can provide greater
benefit in activities of daily living and global functioning in patients with cognitive impairment. Because our study is preliminary,
larger double-blind studies are needed to confirm the results.
mowlaar@sums.ac.irDoes serotonin augmentation have any effect on
cognition and activities of daily living in dementia
related to Alzheimer’s? A double-blind, placebo-
controlled clinical trial
Arash Mowla, Masoud Mosavinasab, Hasan Haghshenas and
Afshin Borhani Haghighi
Shiraz University of Medical Sciences, Iran
J Neurol Neurosci 2018, Volume: 2
DOI: 10.21767/2471-8548-C1-003